Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial

PURPOSE: To report the clinical efficacy of sorafenib and to evaluate biomarkers associated with sorafenib clinical benefit in the BATTLE program. PATIENTS AND METHODS: Patients with previously treated non-small–cell lung cancer (NSCLC) received sorafenib until progression or unacceptable toxicity....

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Blumenschein, George R., Saintigny, Pierre, Liu, Suyu, Kim, Edward S., Tsao, Anne S., Herbst, Roy S., Alden, Christine, Lee, J. Jack, Tang, Ximing, Stewart, David J., Kies, Merrill S., Fossella, Frank V., Tran, Hai T., Mao, L., Hicks, Marshall E., Erasmus, Jeremy, Gupta, Sanjay, Girard, Luc, Peyton, Michael, Diao, Lixia, Wang, Jing, Davis, Suzanne E., Minna, John, Wistuba, Ignacio, Hong, Waun K., Heymach, John V., Lippman, Scott M.
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3905243/
https://ncbi.nlm.nih.gov/pubmed/24166906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1818
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires